- TAAT (TAAT) subsidiary Beyond Alternatives has begun producing the second batch of Jayvees edibles
- The news follows Jayvees’ sold-out initial commercial run over a 14-day period last month
- Jayvees Delta 9 and CBD products are sold in eleven U.S. states as well as Puerto Rico
- TAAT is a vertically integrated consumer product and distribution company focused on tobacco and reduced-risk alternatives, hemp and kratom
- TAAT Global Alternatives (TAAT) is unchanged trading at $0.36 per share
TAAT (TAAT) subsidiary Beyond Alternatives has begun producing the second batch of Jayvees edibles.
The news follows Jayvees’ sold-out initial commercial run over a 14-day period last month.
The second batch will be 13-per-cent larger than the first and is expected to be ready to ship later this month, with four wholesale pre-orders confirmed.
Retailers are reporting that adult consumers purchase an average of ten single-serving units per transaction.
Jayvees Delta 9 and CBD products are sold in eleven U.S. states as well as in Puerto Rico.
“We are excited about the early-stage success of Jayvees as we expand our footprint in the CPG space throughout the United States. Retailers seem to be further embracing edibles and other similar product offerings in 2023, and it is apparent that the Jayvees brand is resonating with adult consumers at the retail level,” stated Michael Saxon, TAAT’s CEO.
TAAT is a vertically integrated consumer product and distribution company focused on tobacco and reduced-risk alternatives, hemp and kratom.
TAAT Global Alternatives (TAAT) is unchanged trading at $0.36 per share as of 10:27 am EST.
